Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) has been assigned a consensus rating of “Buy” from the six ratings firms that are currently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 12 month price target among brokers that have issued a report on the stock in the last year is $8.25.

A number of research analysts have issued reports on the stock. BidaskClub lowered shares of Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 26th. HC Wainwright set a $9.00 target price on shares of Pieris Pharmaceuticals and gave the company a “buy” rating in a report on Friday. Rodman & Renshaw assumed coverage on shares of Pieris Pharmaceuticals in a report on Tuesday, May 30th. They issued a “buy” rating and a $9.00 target price on the stock. Finally, TheStreet lowered shares of Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a report on Monday, June 12th.

COPYRIGHT VIOLATION NOTICE: “Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Given Average Rating of “Buy” by Brokerages” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/11/pieris-pharmaceuticals-inc-nasdaqpirs-given-average-rating-of-buy-by-brokerages.html.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 4.63 on Friday. Pieris Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $6.20. The stock’s market capitalization is $200.97 million. The firm’s 50-day moving average is $5.35 and its 200-day moving average is $3.55.

Pieris Pharmaceuticals (NASDAQ:PIRS) last released its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.16 by $0.35. The firm had revenue of $1.34 million during the quarter, compared to analysts’ expectations of $32.30 million. Pieris Pharmaceuticals had a negative net margin of 459.73% and a negative return on equity of 123.78%. On average, equities research analysts predict that Pieris Pharmaceuticals will post ($0.70) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PIRS. TIAA CREF Investment Management LLC purchased a new position in Pieris Pharmaceuticals during the second quarter worth about $649,000. Teachers Advisors LLC bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $308,000. Sphera Funds Management LTD. raised its position in shares of Pieris Pharmaceuticals by 10.0% in the second quarter. Sphera Funds Management LTD. now owns 1,100,000 shares of the biotechnology company’s stock valued at $5,566,000 after buying an additional 100,000 shares during the last quarter. Bank of New York Mellon Corp bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $359,000. Finally, State of Wisconsin Investment Board bought a new position in shares of Pieris Pharmaceuticals during the second quarter valued at $132,000. Institutional investors own 44.88% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.